
DUO-E | D9311C00001
NCT04269200
JCP078
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E)
Status:
Opening Soon

III
Phase

1st
Line of Therapy

Advanced / Metastatic
Disease Stage

Biomarker(s)
N/A
Investigational
Product
Durvalumab
IgG1k monoclonal antibody
Treatment Arms
o Active Comparator: Arm A (control)
o Experimental: Arm B (durvalumab+placebo)
o Experimental: Arm C (durvalumab+olaparib)